{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T23:12:52Z","timestamp":1783120372716,"version":"3.54.6"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T00:00:00Z","timestamp":1645401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["HD100535 HD098131 HD067244 HD093758 HD095520"],"award-info":[{"award-number":["HD100535 HD098131 HD067244 HD093758 HD095520"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["ES027801 ES032347"],"award-info":[{"award-number":["ES027801 ES032347"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["AR076029"],"award-info":[{"award-number":["AR076029"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["NS118233"],"award-info":[{"award-number":["NS118233"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p>Valproic acid (VPA, valproate, Depakote) is a commonly used anti-seizure medication (ASM) in the treatment of epilepsy and a variety of other neurological disorders. While VPA and other ASMs are efficacious for management of seizures, they also increase the risk for adverse pregnancy outcomes, including neural tube defects (NTDs). Thus, the utility of these drugs during pregnancy and in women of childbearing potential presents a continuing public health challenge. Elucidating the underlying genetic or metabolic risk factors for VPA-affected pregnancies may lead to development of non-teratogenic ASMs, novel prevention strategies, or more targeted methods for managing epileptic pregnancies. To address this challenge, we performed unbiased, whole embryo metabolomic screening of E8.5 mouse embryos from two inbred strains with differential susceptibility to VPA-induced NTDs. We identified metabolites of differential abundance between the two strains, both in response to VPA exposure and in the vehicle controls. Notable enriched pathways included lipid metabolism, carnitine metabolism, and several amino acid pathways, especially cysteine and methionine metabolism. There also was increased abundance of \u03c9-oxidation products of VPA in the more NTD-sensitive strain, suggesting differential metabolism of the drug. Finally, we found significantly reduced levels of hypotaurine in the susceptible strain regardless of VPA status. Based on this information, we hypothesized that maternal supplementation with L-carnitine (400\u00a0mg\/kg), coenzyme A (200\u00a0mg\/kg), or hypotaurine (350\u00a0mg\/kg) would reduce VPA-induced NTDs in the sensitive strain and found that administration of hypotaurine prior to VPA exposure significantly reduced the occurrence of NTDs by close to one-third compared to controls. L-carnitine and coenzyme A reduced resorption rates but did not significantly reduce NTD risk in the sensitive strain. These results suggest that genetic variants or environmental exposures influencing embryonic hypotaurine status may be factors in determining risk for adverse pregnancy outcomes when managing the health care needs of pregnant women exposed to VPA or other ASMs.<\/jats:p>","DOI":"10.3389\/fcell.2022.832492","type":"journal-article","created":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T10:56:19Z","timestamp":1645440979000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Embryonic Hypotaurine Levels Contribute to Strain-Dependent Susceptibility in Mouse Models of Valproate-Induced Neural Tube Defects"],"prefix":"10.3389","volume":"10","author":[{"given":"John W.","family":"Steele","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying Linda","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nellie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan J.","family":"Wlodarczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabeel","family":"Attarwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhu","family":"Venkatesalu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Cabrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven S.","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard H.","family":"Finnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.annfar.2011.05.019","article-title":"Cas d'une intoxication s\u00e9v\u00e8re \u00e0 l'acide valpro\u00efque : int\u00e9r\u00eat d'un traitement par \u00e9puration extrar\u00e9nale combin\u00e9 \u00e0 la L-carnitine","volume":"30","author":"Alluin","year":"2011","journal-title":"Ann. Fran\u00e7aises d'Anesth\u00e9sie de R\u00e9animation"},{"key":"B2","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1042\/bj2560251","article-title":"The Antioxidant Action of Taurine, Hypotaurine and Their Metabolic Precursors","volume":"256","author":"Aruoma","year":"1988","journal-title":"Biochem. J."},{"key":"B3","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1124\/dmd.119.086439","article-title":"Maternal Plasma L-Carnitine Reduction during Pregnancy Is Mainly Attributed to OCTN2-Mediated Placental Uptake and Does Not Result in Maternal Hepatic Fatty Acid \u03b2-Oxidation Decline","volume":"47","author":"Bai","year":"2019","journal-title":"Drug Metab. Dispos"},{"key":"B4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/s0890-6238(00)00109-x","article-title":"Does Genomic Imprinting Contribute to Valproic Acid Teratogenicity?","volume":"15","author":"Beck","year":"2001","journal-title":"Reprod. Toxicol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/s0890-6238(99)00038-6","article-title":"Contributions of Dam and Conceptus to Differences in Sensitivity to Valproic Acid Among C57 Black and SWV Mice","volume":"13","author":"Beck","year":"1999","journal-title":"Reprod. Toxicol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/bdrc.20027","article-title":"Mechanisms Regulating Toxicant Disposition to the Embryo during Early Pregnancy: an Interspecies Comparison","volume":"72","author":"Carney","year":"2004","journal-title":"Birth Defect Res. C"},{"key":"B7","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1177\/088307389801301104","article-title":"Serum Carnitine Levels in Epileptic Children before and during Treatment with Valproic Acid, Carbamazepine, and Phenobarbital","volume":"13","author":"Castro-Gago","year":"1998","journal-title":"J. Child. Neurol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e2025570","DOI":"10.1001\/jamanetworkopen.2020.25570","article-title":"Association of Prenatal Exposure to Valproate and Other Antiepileptic Drugs with Intellectual Disability and Delayed Childhood Milestones","volume":"3","author":"Daugaard","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"B9","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/1471-2393-14-150","article-title":"Creatine Supplementation during Pregnancy: Summary of Experimental Studies Suggesting a Treatment to Improve Fetal and Neonatal Morbidity and Reduce Mortality in High-Risk Human Pregnancy","volume":"14","author":"Dickinson","year":"2014","journal-title":"BMC Pregnancy Childbirth"},{"key":"B10","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1586\/17512433.2014.871202","article-title":"Evidence for a Potential Protective Effect of Carnitine-Pantothenic Acid Co-treatment on Valproic Acid-Induced Hepatotoxicity","volume":"7","author":"Felker","year":"2014","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B11","first-page":"71","article-title":"The Biological Oxidation of Hypotaurine to Taurine: Hypotaurine as an Antioxidant","volume":"179","author":"Fellman","year":"1985","journal-title":"Prog. Clin. Biol. Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/tera.1420380403","article-title":"Common Hierarchies of Susceptibility to the Induction of Neural Tube Defects in Mouse Embryos by Valproic Acid and its 4-Propyl-4-Pentenoic Acid Metabolite","volume":"38","author":"Finnell","year":"1988","journal-title":"Teratology"},{"key":"B13","first-page":"162","article-title":"Common Hierarchies of Susceptibility to Teratogen-Induced Neural Tube Defects in the Mouse","volume":"5","author":"Finnell","year":"1985","journal-title":"Proc. Grnwd Genet. Ctr"},{"key":"B14","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/j.1749-6632.2000.tb06886.x","article-title":"Genetic Basis of Susceptibility to Environmentally Induced Neural Tube Defects","volume":"919","author":"Finnell","year":"2000","journal-title":"Ann. N. Y Acad. Sci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/(sici)1096-8628(19970613)70:3<303::aid-ajmg17>3.0.co;2-p","article-title":"Strain-dependent Alterations in the Expression of Folate Pathway Genes Following Teratogenic Exposure to Valproic Acid in a Mouse Model","volume":"70","author":"Finnell","year":"1997","journal-title":"Am. J. Med. Genet."},{"key":"B16","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1080\/10715760801999727","article-title":"The Protective Effect of Hypotaurine and Cysteine Sulphinic Acid on Peroxynitrite-Mediated Oxidative Reactions","volume":"42","author":"Fontana","year":"2008","journal-title":"Free Radic. Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1023\/b:nere.0000010439.99991.cf","article-title":"Antioxidant Properties of Sulfinates: Protective Effect of Hypotaurine on Peroxynitrite-dependent Damage","volume":"29","author":"Fontana","year":"2004","journal-title":"Neurochem. Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003495-198734010-00001","article-title":"l-Carnitine","volume":"34","author":"Goa","year":"1987","journal-title":"Drugs"},{"key":"B19","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/0304-4165(91)90187-l","article-title":"Antioxidant Role and Subcellular Location of Hypotaurine and Taurine in Human Neutrophils","volume":"1073","author":"Green","year":"1991","journal-title":"Biochim. Biophys. Acta (Bba) - Gen. Subjects"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1111\/j.1528-1167.2009.02129.x","article-title":"Management Issues for Women with Epilepsy-Focus on Pregnancy (An Evidence-Based Review): II. Teratogenesis and Perinatal Outcomes","volume":"50","author":"Harden","year":"2009","journal-title":"Epilepsia"},{"key":"B21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.eplepsyres.2019.03.009","article-title":"Effects of Levetiracetam and Valproic Acid Treatment on Liver Function Tests, Plasma Free Carnitine and Lipid Peroxidation in Childhood Epilepsies","volume":"153","author":"Haznedar","year":"2019","journal-title":"Epilepsy Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1527-3458.2003.tb00249.x","article-title":"Valproate: Past, Present, and Future","volume":"9","author":"Johannessen","year":"2003","journal-title":"CNS Drug Rev."},{"key":"B23","doi-asserted-by":"publisher","first-page":"4153","DOI":"10.1007\/s11033-021-06428-4","article-title":"Taurine Attenuates Valproic Acid-Induced Hepatotoxicity via Modulation of RIPK1\/RIPK3\/MLKL-Mediated Necroptosis Signaling in Mice","volume":"48","author":"Khodayar","year":"2021","journal-title":"Mol. Biol. Rep."},{"key":"B24","first-page":"1167","article-title":"Hepatic Diseases Caused by Drugs","volume":"86","author":"Lammert","year":"1997","journal-title":"Praxis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1080\/15563650902752376","article-title":"Carnitine in the Treatment of Valproic Acid-Induced Toxicity","volume":"47","author":"Lheureux","year":"2009","journal-title":"Clin. Toxicol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"107928","DOI":"10.1016\/j.yebeh.2021.107928","article-title":"Precision Medicine in Women with Epilepsy: The challenge, Systematic Review, and Future Direction","volume":"118","author":"Li","year":"2021","journal-title":"Epilepsy Behav."},{"key":"B27","first-page":"133","article-title":"Valproic Acid Induced Intracellular GSH-Redox Imbalance and Apoptosis of Leukemic Cells Resistant to Dexamethasone and Doxorubicin","volume":"40","author":"Liu","year":"2009","journal-title":"Sichuan Da Xue Xue Bao Yi Xue Ban"},{"key":"B28","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00335-004-2345-9","article-title":"Mapping a Chromosomal Locus for Valproic Acid-Inducedexencephaly in Mice","volume":"15","author":"Lundberg","year":"2004","journal-title":"Mamm. Genome"},{"key":"B29","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/9781118936979.ch51","article-title":"Valproate","volume-title":"The Treatment of Epilepsy","author":"Marson","year":"2015"},{"key":"B30","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1212\/01.wnl.0000227919.81208.b2","article-title":"In Utero antiepileptic Drug Exposure: Fetal Death and Malformations","volume":"67","author":"Meador","year":"2006","journal-title":"Neurology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eplepsyres.2008.04.022","article-title":"Pregnancy Outcomes in Women with Epilepsy: a Systematic Review and Meta-Analysis of Published Pregnancy Registries and Cohorts","volume":"81","author":"Meador","year":"2008","journal-title":"Epilepsy Res."},{"key":"B32","first-page":"137","article-title":"Effect of Chronic Valproic Acid Treatment on Plasma and Urine Carnitine Levels in Children: Decreased Urinary Excretion","volume":"28","author":"Melegh","year":"1987","journal-title":"Acta Paediatr. Hung"},{"key":"B33","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/s0022-3476(94)70218-7","article-title":"Carnitine-dependent Changes of Metabolic Fuel Consumption during Long-Term Treatment with Valproic Acid","volume":"125","author":"Melegh","year":"1994","journal-title":"J. Pediatr."},{"key":"B34","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/j.1741-4520.1996.tb00622.x","article-title":"Carnitine and Coenzyme A Decrease Valproic Acid-Induced Neural Tube Defects in Mice","volume":"36","author":"Nagao","year":"1996","journal-title":"Congenit. Anom."},{"key":"B35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A Simple Practice Guide for Dose Conversion between Animals and Human","volume":"7","author":"Nair","year":"2016","journal-title":"J. Basic Clin. Pharma"},{"key":"B36","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/tera.1420380113","article-title":"Strain Differences in the Teratogenicity Induced by Sodium Valproate in Cultured Mouse Embryos","volume":"38","author":"Naruse","year":"1988","journal-title":"Teratology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/0041-008x(85)90081-x","article-title":"Teratogenic Valproic Acid Concentrations: Infusion by Implanted Minipumps vs Conventional Injection Regimen in the Mouse","volume":"80","author":"Nau","year":"1985","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/bdd.2510030405","article-title":"Pharmacokinetics of Valproic Acid and Metabolites in Mouse Plasma and Brain Following Constant-Rate Application of the Drug and its Unsaturated Metabolite with an Osmotic Delivery System","volume":"3","author":"Nau","year":"1982","journal-title":"Biopharm. Drug Dispos."},{"key":"B39","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.placenta.2015.02.014","article-title":"Protective Effect of Hypotaurine against Oxidative Stress-Induced Cytotoxicity in Rat Placental Trophoblasts","volume":"36","author":"Nishimura","year":"2015","journal-title":"Placenta"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e105423","DOI":"10.1371\/journal.pone.0105423","article-title":"Fetal Growth Retardation and Lack of Hypotaurine in Ezrin Knockout Mice","volume":"9","author":"Nishimura","year":"2014","journal-title":"PLoS One"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1248\/bpb.b18-00168","article-title":"Hypotaurine Is a Substrate of GABA Transporter Family Members GAT2\/Slc6a13 and TAUT\/Slc6a6","volume":"41","author":"Nishimura","year":"2018","journal-title":"Biol. Pharm. Bull."},{"key":"B42","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.placenta.2005.10.002","article-title":"L-carnitine Is Synthesized in the Human Fetal-Placental Unit: Potential Roles in Placental and Fetal Metabolism","volume":"27","author":"Oey","year":"2006","journal-title":"Placenta"},{"key":"B43","first-page":"244","article-title":"Carnitine Deficiency as an Adverse Effect of Treatment with Valproic Acid","volume":"24","author":"Opala","year":"1990","journal-title":"Neurol. Neurochir Pol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/j.1535-7511.2006.00140.x","article-title":"EURAP Outcomes for Seizure Control during Pregnancy: Useful and Encouraging Data","volume":"6","author":"Pennell","year":"2006","journal-title":"Epilepsy Curr."},{"key":"B45","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/WCO.0b013e32832923d7","article-title":"Managing Antiepileptic Drugs during Pregnancy and Lactation","volume":"22","author":"Sabers","year":"2009","journal-title":"Curr. Opin. Neurol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3164\/jcbn.09-91","article-title":"Hypotaurine Is an Energy-Saving Hepatoprotective Compound against Ischemia-Reperfusion Injury of the Rat Liver","volume":"46","author":"Sakuragawa","year":"2010","journal-title":"J. Clin. Biochem. Nutr."},{"key":"B47","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/j.1600-0404.2007.00830.x","article-title":"Teratogenicity of Antiepileptic Drugs: Role of Drug Metabolism and Pharmacogenomics","volume":"116","author":"Sankar","year":"2007","journal-title":"Acta Neurol. Scand."},{"key":"B48","volume-title":"The History of Epileptic Therapy: An Account of How Medication Was Developed","author":"Scott","year":"1993"},{"key":"B49","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1203\/01.PDR.0000134252.02876.55","article-title":"Carnitine Content and Expression of Mitochondrial \u03b2-Oxidation Enzymes in Placentas of Wild-type (OCTN2+\/+) and OCTN2 Null (OCTN2\u2212\/\u2212) Mice","volume":"56","author":"Shekhawat","year":"2004","journal-title":"Pediatr. Res."},{"key":"B50","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/nrm.2016.110","article-title":"Coenzyme A: to Make it or Uptake it?","volume":"17","author":"Sibon","year":"2016","journal-title":"Nat. Rev. Mol. Cel Biol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10545-008-0841-x","article-title":"Valproic Acid Metabolism and its Effects on Mitochondrial Fatty Acid Oxidation: a Review","volume":"31","author":"Silva","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1002\/pd.5760","article-title":"Approaches to Studying the Genomic Architecture of Complex Birth Defects","volume":"40","author":"Taiwo","year":"2020","journal-title":"Prenatal Diagn."},{"key":"B53","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.clineuro.2010.01.002","article-title":"The Influence of Cytochrome Oxidase CYP2A6, CYP2B6, and CYP2C9 Polymorphisms on the Plasma Concentrations of Valproic Acid in Epileptic Patients","volume":"112","author":"Tan","year":"2010","journal-title":"Clin. Neurol. Neurosurg."},{"key":"B54","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/s1474-4422(12)70103-5","article-title":"Teratogenic Effects of Antiepileptic Drugs","volume":"11","author":"Tomson","year":"2012","journal-title":"Lancet Neurol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.ncl.2009.06.006","article-title":"Teratogenic Effects of Antiepileptic Medications","volume":"27","author":"Tomson","year":"2009","journal-title":"Neurol. Clin."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.jocn.2012.05.003","article-title":"Dose Issues in Antiepileptic Therapy","volume":"19","author":"Vajda","year":"2012","journal-title":"J. Clin. Neurosci."},{"key":"B57","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/bf02788969","article-title":"Carnitine Deficiency during Valproic Acid Treatment","volume":"65","author":"Van Wouwe","year":"1995","journal-title":"Int. J. Vitam Nutr. Res."},{"key":"B58","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1124\/dmd.119.089995","article-title":"Flavin-Containing Monooxygenase 1 Catalyzes the Production of Taurine from Hypotaurine","volume":"48","author":"Veeravalli","year":"2020","journal-title":"Drug Metab. Dispos"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1222002","DOI":"10.1126\/science.1222002","article-title":"The Continuing challenge of Understanding, Preventing, and Treating Neural Tube Defects","volume":"339","author":"Wallingford","year":"2013","journal-title":"Science"},{"key":"B60","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/(sici)1096-9926(199612)54:6<284::aid-tera3>3.0.co;2-z","article-title":"Valproic Acid-Induced Changes in Gene Expression during Neurulation in a Mouse Model","volume":"54","author":"Wlodarczyk","year":"1996","journal-title":"Teratology"},{"key":"B61","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1002\/ajmg.a.35438","article-title":"Antiepileptic Drugs and Pregnancy Outcomes","author":"Wlodarczyk","year":"2012","journal-title":"Am. J. Med. Genet."},{"key":"B62","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2165\/00003088-198815060-00002","article-title":"Clinical Pharmacokinetics of Valproic Acid - 1988","volume":"15","author":"Zaccara","year":"1988","journal-title":"Clin. Pharmacokinet."},{"key":"B63","doi-asserted-by":"publisher","first-page":"35733","DOI":"10.1074\/jbc.M112.368175","article-title":"Deletion of the \u03b3-Aminobutyric Acid Transporter 2 (GAT2 and SLC6A13) Gene in Mice Leads to Changes in Liver and Brain Taurine Contents","volume":"287","author":"Zhou","year":"2012","journal-title":"J. Biol. Chem."}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2022.832492\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T10:56:34Z","timestamp":1645440994000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2022.832492\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,21]]},"references-count":63,"alternative-id":["10.3389\/fcell.2022.832492"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2022.832492","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,21]]},"article-number":"832492"}}